|
By Brian Wilson, Contributor
|
|
Thursday, 02 August 2012 00:00 |
 Dendreon (DNDN) has been a disastrous holding for many investors who may have been initially optimistic about the company’s drug PROVENGE. I initiated coverage on the distressed biotech name on July 21st of this year with a hold rating. I certainly did not want my followers to buy any more of the stock, and I had my reservations about a cold-blooded sell recommendation due to the extreme bearishness surrounding the company.
|
|
Read more...
|
|
By M.E.Garza
|
|
Wednesday, 01 August 2012 02:06 |
 No doubt, one of the biggest biotech surprises out of the starting gate this year has been Medgenics Inc. (AMEX:MDGN). The stock ran big shortly after their introduction to the market as shares traded from $2.08 to $16.43 in short order-- an impressive run fueled in part by the company's extremely low float and excited reaction by investors.
|
|
Read more...
|
|
By Ray Dirks of Ray Dirks Research
|
|
Tuesday, 31 July 2012 07:23 |
 This morning, Pluristem Therapeutics (NASDAQ:PSTI) is once again making news. This time with a new way to treat Pulmonary fibrosis; where a person's lungs become so scarred that breathing is impossible. It strikes 5 million people per year around the world, and 200,000 in the US. Most die because there is no cure.
|
|
Read more...
|
|
By M.E.Garza
|
|
Friday, 27 July 2012 07:42 |
 In a flash note to clients on Friday, Roth Capital Partners’ analyst Joseph Pantginis, Ph.D.,says that Thursday’s FDA approval for Amarin Corporation’s (NASDAQ:AMRN) Vascepa bodes well for Neptune Technologies & Bioressources’ (Nasdaq:NEPT) (TSX:NTB) underlying and growing core NKO business as well as the pharmaceutical opportunity with Acasti's CaPre.
|
|
Read more...
|
|
By Brian Wilson, Contributor
|
|
Friday, 27 July 2012 06:15 |
|
Repros Therapeutics Inc. (NASDAQ:RPRX) caught the attention of biotech investors after its ~120% rally in May, which sent the stock from a market cap of approximately $63 million to its current $140 million. Biotech investors looking at this firm’s history can quickly note that the IPO for RPRX was initiated all the way back in 1993.
|
|
Read more...
|
|
By Brian Wilson, Contributor
|
|
Thursday, 26 July 2012 07:20 |
 When I last covered Onyx Pharmaceuticals (NASDAQ:ONXX) on June 19th, the company was trading at a market capitalization of approximately $3 billion dollars ahead of a review of Kyprolis (carfilzomib) by the FDA’s Oncologic Drugs Advisory Committee (ODAC).
|
|
Read more...
|
|
By Staff and Wire Reports
|
|
Tuesday, 24 July 2012 12:50 |
 In an exclusive video interview with healthcare analyst Avik Roy, Sagent Pharmaceuticals' (NASDAQ:SGNT) President and CEO Jeff Yordon says his specialty pharmaceutical company that develops, manufactures, sources and markets pharmaceutical products is drafting unique contracts with its customers.
|
|
Read more...
|
|
By Brian Wilson, Contributor
|
|
Tuesday, 24 July 2012 04:58 |
|
Dendreon (DNDN), a big name in the prostate cancer world, is struggling to heavily market the drug PROVENGE ® much to the dismay of its shareholders. DNDN was trading around $38/share a year ago, but have fallen more than 80% as a double-whammy of underwhelming sales data and very narrow profit margins brought the company into negative-EPS territory.
|
|
Read more...
|
|
By Scott Matusow, Contributor
|
|
Monday, 23 July 2012 06:26 |
 Trying to find companies that represent the future of the biotech sector can be tricky for investors. The sector currently leads the market because Food and Drug Administration (FDA) regulatory guidance is changing, with restrictions easing, and new guidelines being proposed and implemented.
|
|
Read more...
|
|
By M.E.Garza
|
|
Monday, 23 July 2012 01:52 |
 Shares of Array BioPharma (NASDAQ:ARRY) have soared since we first told readers that the firm was planning to partner more products.
|
|
Read more...
|
|
|
<< Start < Prev 51 52 53 54 55 56 Next > End >>
|
|
Page 54 of 56 |
